Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc. develops and commercializes research-use proteomics products centered on its Proteograph Product Suite. The suite integrates proprietary engineered nanoparticles, optimized consumables, automation instrumentation and analytical software for proteomic analysis in research laboratories, academic institutions and biopharmaceutical settings.
SEER news commonly covers financial results and outlook, Proteograph adoption, research collaborations in multi-omic and population-scale studies, intellectual-property developments involving particle-based protein enrichment, and commercial leadership changes. Company updates also include governance and shareholder matters, including board responses to unsolicited proposals, director nominations, rights plans and other capital-structure actions.
Summary not available.
Seer (Nasdaq: SEER) reported second quarter 2026 revenue of $3.1 million, down 23% from $4.1 million a year earlier, mainly from lower product and service revenue amid macro headwinds and elongated sales cycles. Gross profit was $1.5 million with a 49% gross margin.
Operating expenses fell 19% to $18.3 million, driven largely by lower employee and stock-based compensation, reducing net loss to $16.9 million from $19.4 million. The company ended June 30, 2026 with about $209.5 million in cash, cash equivalents and investments and had repurchased roughly 200,000 Class A shares. Seer reaffirmed its full-year 2026 revenue outlook of $16–$18 million, implying about 3% growth at the midpoint over 2025.
Seer (Nasdaq: SEER) announced it will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston, MA. Seer’s management is scheduled to present on Wednesday, August 12 from 8:00 a.m. to 8:25 a.m. Eastern Time. A live webcast and archived replay will be available on the Investor section of the company’s website.
Seer (Nasdaq: SEER) announced it will report its second quarter 2026 financial results on Tuesday, August 11, 2026. Company management will host a webcasted conference call starting at 1:30 p.m. Pacific / 4:30 p.m. Eastern, with live audio and replay available on Seer’s investor website.
Seer (Nasdaq: SEER) confirmed receipt of two further revised, unsolicited, non-binding acquisition proposals for all outstanding shares of its Class A common stock. On July 28, 2026, the Radoff-JEC Group offered $2.55 per share in cash plus a contingent value right.
On July 29, 2026, Omid Farokhzad, M.D., Seer’s Chair and CEO, submitted a revised proposal for $2.45 per share in cash plus two separate contingent value rights. According to Seer, its previously constituted Special Committee, with advisors, will review both proposals and other alternatives. No stockholder action is required at this time.
Seer (Nasdaq: SEER) reported that, based on preliminary results from its 2026 Annual Meeting of Stockholders, stockholders voted to re-elect all seven director nominees to the Board. The company said it remains focused on executing its strategy, including expanding platform utilization and commercialization with cost discipline. Final voting results will be certified by an independent inspector and filed on Form 8-K with the SEC.
Summary not available.
Radoff-JEC Group, which reports owning approximately 7.7% of Seer’s (NASDAQ: SEER) outstanding common stock, is urging stockholders to use the WHITE proxy card to elect its three independent nominees, Howard H. Berman, Ph.D., Luis E. Rinaldini and Joshua S. Horowitz, to Seer’s Board.
According to Radoff-JEC Group, all three major independent proxy advisors – ISS, Glass Lewis and Egan-Jones – recommend voting for its nominees, withholding support from certain incumbent directors, and voting against Seer’s Tax Benefit Preservation Plan. The group cites Seer’s share-price decline of about 97% since its 2020 IPO and advocates installing new independent directors to lead a robust, transparent review of strategic alternatives, including a potential sale of the company.
Summary not available.
Seer (Nasdaq: SEER)/b) announced that a Special Committee of its Board, composed of independent directors Meeta Gulyani and Nicolas Roelofs, Ph.D., has thoroughly reviewed and unanimously rejected an unsolicited, non-binding proposal dated July 1, 2026 from Chair and CEO Omid Farokhzad, M.D. to acquire all outstanding shares of Seer’s Class A common stock for
The Special Committee, advised by independent advisors, determined the proposal is not in the best interests of stockholders because it undervalues Seer and does not reflect its long-term growth prospects. It also concluded that the CVRs, intended to allow stockholders to benefit from future developments related to Seer’s technology, are insufficient to fully value Seer and its growth potential.